Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
MYGN Myriad Genetics Inc
- Stocks
- Healthcare
- NASDAQ: MYGN
Price (delayed)
$4.13
Market cap
$380.69M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.12
Enterprise value
$446.49M
Myriad Genetics Inc., is a leading genetic testing and precision medicine company dedicated to transforming patient lives worldwide. Myriad discovers and commercializes genetic tests that: determine the risk of developing
Highlights
The EPS has soared by 60% YoY and by 21% from the previous quarter
The company's net income has surged by 57% YoY and by 20% QoQ
The quick ratio has declined by 8% year-on-year but it has increased by 2.9% since the previous quarter
The debt has grown by 12% from the previous quarter and by 7% YoY
The company's equity fell by 7% YoY
Key stats
What are the main financial stats of MYGN
Market
Valuations
Earnings
Shares outstanding
92.18M
Market cap
$380.69M
Enterprise value
$446.49M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.53
Price to sales (P/S)
0.45
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.54
Revenue
$831.3M
Gross profit
$582M
Operating income
-$124.5M
Net income
-$101.4M
EBIT
-$123.8M
EBITDA
-$53.9M
Free cash flow
-$35.8M
Per share
Balance sheet
Liquidity
EPS
-$1.12
EPS diluted
-$1.12
Free cash flow per share
-$0.39
Book value per share
$7.72
Revenue per share
$9.1
TBVPS
$5.06
Total assets
$1.01B
Total liabilities
$301.2M
Debt
$157.6M
Equity
$704.9M
Working capital
$136.1M
Debt to equity
0.22
Current ratio
1.9
Quick ratio
1.4
Net debt/EBITDA
-1.22
Margins
Efficiency
Dividend
EBITDA margin
-6.5%
Gross margin
70%
Net margin
-12.2%
Operating margin
-15%
Return on assets
-9.7%
Return on equity
-14.1%
Return on invested capital
-33.4%
Return on capital employed
-14.5%
Return on sales
-14.9%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
MYGN stock price
How has the Myriad Genetics stock price performed over time
Intraday
0.49%
1 week
6.17%
1 month
-47.79%
1 year
-83.22%
YTD
-69.88%
QTD
-53.44%
Financial performance
How have Myriad Genetics's revenue and profit performed over time
Revenue
$831.3M
Gross profit
$582M
Operating income
-$124.5M
Net income
-$101.4M
Gross margin
70%
Net margin
-12.2%
The net margin has soared by 60% YoY and by 20% from the previous quarter
The company's net income has surged by 57% YoY and by 20% QoQ
The company's operating margin has surged by 50% YoY but it fell by 2% QoQ
The operating income rose by 47% YoY
Price vs fundamentals
How does MYGN's price correlate with its fundamentals
Growth
What is Myriad Genetics's growth rate over time
Valuation
What is Myriad Genetics stock price valuation
P/E
N/A
P/B
0.53
P/S
0.45
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.54
The EPS has soared by 60% YoY and by 21% from the previous quarter
MYGN's price to book (P/B) is 77% lower than its last 4 quarters average of 2.3 and 75% lower than its 5-year quarterly average of 2.1
The company's equity fell by 7% YoY
The P/S is 82% lower than the 5-year quarterly average of 2.5 and 79% lower than the last 4 quarters average of 2.1
Myriad Genetics's revenue has increased by 7% YoY
Efficiency
How efficient is Myriad Genetics business performance
MYGN's return on equity has surged by 56% year-on-year and by 19% since the previous quarter
Myriad Genetics's return on assets has surged by 52% YoY and by 18% QoQ
The ROS has soared by 50% YoY but it has contracted by 3.5% from the previous quarter
The return on invested capital has grown by 42% year-on-year but it has declined by 3.1% since the previous quarter
Dividends
What is MYGN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for MYGN.
Financial health
How did Myriad Genetics financials performed over time
The company's total liabilities fell by 14% YoY and by 8% QoQ
Myriad Genetics's total assets has decreased by 9% YoY and by 2.1% from the previous quarter
The debt is 78% less than the equity
The debt to equity is up by 16% year-on-year and by 10% since the previous quarter
The debt has grown by 12% from the previous quarter and by 7% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.